Boehringer Ingelheim

This little-known biopharmaceutical outfit has signed not just one but seven partnership pacts with Big Pharmas to help develop some of its products. Micromet's No. 1 appeal: It's developing novel antibody-based drugs to treat cancer, inflammatory and autoimmune diseases.

Angiotensin-receptor blockers, a common class of blood pressure medications, have been linked to an increased risk of cancer in a recent study. These widely used drugs include medicines such as Boehringer's Micardis, Merck's Cozaar and Hyzaar, and Novartis's Diovan.